Athira Pharma, Inc. (ATHA)

2,6400 +0,0800 (+3,13%) Börsenschluss: 04:00PM EDT

Athira Pharma, Inc.

18706 North Creek Parkway
Suite 104
Bothell, WA 98011
United States
425 620 8501
https://www.athira.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 65

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Mark J. Litton M.B.A., Ph.D.	President, CEO & Director	882,7k	N/A	1968
Mr. Andrew W. Gengos	CFO & Chief Business Officer	396,16k	N/A	1964
Ms. Rachel P. Lenington M.B.A.	Chief Development Officer & COO	578k	N/A	1973
Dr. Kevin Church Ph.D.	Chief Scientific Officer	123,67k	N/A	1985
Ms. Julie Rathbun	Head of Investor Relations	N/A	N/A	N/A
Mr. Mark F. Worthington J.D.	General Counsel & Corporate Secretary	503,83k	N/A	1966
Ms. Samantha Willing	Chief People Officer	N/A	N/A	N/A
Dr. Javier San Martin M.D.	Chief Medical Officer	N/A	N/A	1965

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Corporate Governance

Athira Pharma, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 5, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.